Plus Therapeutics to Host Virtual KOL Event on New Phase 2 ReSPECT-GBM Data in Recurrent Glioblastoma Presented at the Society for NeuroOncology (SNO) Conference on Monday, November 20, 2023
AUSTIN, Texas, Nov. 15, 2023 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced it will host a virtual KOL event on Monday, November 20, 2023 at 10:00 AM ET to discuss new Phase 2 ReSPECT-GBM data in recurrent glioblastoma presented at the Society for NeuroOncology (SNO) Conference. To register, click here.
Related news for (PSTV)
- Breaking News: MoBot’s Latest Update as of 08/06/25 01:00 PM
- Breaking News: MoBot’s Latest Update as of 08/05/25 08:00 AM
- Breaking News: MoBot’s Latest Update as of 08/04/25 11:00 AM
- Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic
- Breaking News: MoBot’s Latest Update as of 07/31/25 08:00 AM